GLENMARK LIFE SCIENCES
|
GLENMARK LIFE SCIENCES Last 5 Year Financial Ratios History
[Standalone]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 38.11 | 34.17 | 358.76 | 1,597.44 | 997.92 |
| CEPS(Rs) | 41.55 | 37.27 | 35.71 | 31.77 | 19.93 |
| DPS(Rs) | 21.00 | 21.00 | - | - | - |
| Book NAV/Share(Rs) | 173.97 | 167.38 | 768.11 | 2,049.45 | 449.62 |
| Tax Rate(%) | 25.72 | 25.88 | 25.35 | 25.64 | 14.33 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 29.56 | 28.98 | 31.28 | 30.66 | 27.88 |
| EBIT Margin(%) | 28.96 | 27.89 | 29.55 | 29.53 | 25.82 |
| Pre Tax Margin(%) | 28.93 | 26.58 | 24.92 | 27.35 | 25.75 |
| PAT Margin (%) | 21.49 | 19.70 | 18.60 | 20.34 | 22.07 |
| Cash Profit Margin (%) | 23.43 | 21.48 | 20.37 | 22.25 | 24.24 |
| Performance Ratios | |||||
| ROA(%) | 15.43 | 16.57 | 17.82 | 19.56 | 26.51 |
| ROE(%) | 22.33 | 29.87 | 60.91 | 127.84 | 451.05 |
| ROCE(%) | 30.01 | 42.24 | 96.75 | 185.60 | 527.74 |
| Asset Turnover(x) | 0.72 | 0.84 | 0.96 | 0.96 | 1.20 |
| Sales/Fixed Asset(x) | 2.65 | 3.13 | 3.03 | 2.88 | 3.73 |
| Working Capital/Sales(x) | 1.61 | 1.54 | 10.64 | -10.45 | -1.97 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.38 | 0.32 | 0.33 | 0.35 | 0.27 |
| Receivable days | 124.34 | 111.01 | 121.50 | 128.84 | 92.26 |
| Inventory Days | 94.11 | 88.40 | 89.45 | 96.46 | 82.54 |
| Payable days | 130.60 | 94.72 | 87.85 | 105.53 | 100.55 |
| Valuation Parameters | |||||
| PER(x) | 10.28 | 13.43 | - | - | - |
| PCE(x) | 9.43 | 12.32 | - | - | - |
| Price/Book(x) | 2.25 | 2.74 | - | - | - |
| Yield(%) | 5.36 | 4.58 | - | - | - |
| EV/Net Sales(x) | 2.08 | 2.41 | -0.06 | -0.01 | - |
| EV/Core EBITDA(x) | 6.69 | 8.10 | -0.19 | -0.02 | - |
| EV/EBIT(x) | 7.13 | 8.62 | -0.20 | -0.02 | - |
| EV/CE(x) | 1.39 | 1.80 | -0.05 | - | - |
| M Cap / Sales | 2.22 | 2.65 | - | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 1.79 | 12.63 | 22.63 | 73.43 | - |
| Core EBITDA Growth(%) | 6.42 | 6.57 | 22.30 | 95.01 | - |
| EBIT Growth(%) | 6.12 | 6.16 | 22.86 | 98.59 | - |
| PAT Growth(%) | 11.52 | 19.10 | 12.29 | 60.08 | - |
| EPS Growth(%) | 11.52 | -90.47 | -77.54 | 60.08 | 329.94 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | - |
| Current Ratio(x) | 2.32 | 2.85 | 1.12 | 0.89 | 0.67 |
| Quick Ratio(x) | 1.73 | 2.16 | 0.77 | 0.57 | 0.38 |
| Interest Cover(x) | 1,150.19 | 21.20 | 6.38 | 13.56 | 378.35 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of GLENMARK LIFE SCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK LIFE SCIENCES | ₹10,282.7 Cr | 4.3% | -13.3% | 82.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹369,402.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹109,341.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,341.0 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹99,176.4 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹96,543.1 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
GLENMARK LIFE SCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK LIFE SCIENCES | 4.3% |
-13.3% |
82.6% |
| SENSEX | -0.8% |
1.4% |
22.9% |
You may also like the below Video Courses
